This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. RNTX, OKUR, BDRX, ITRM, ATHE, AKTX, ACRV, ELYM, BRNS, and MDCXShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Rein Therapeutics (RNTX), OnKure Therapeutics (OKUR), Biodexa Pharmaceuticals (BDRX), Iterum Therapeutics (ITRM), Alterity Therapeutics (ATHE), Akari Therapeutics (AKTX), Acrivon Therapeutics (ACRV), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), and Medicus Pharma (MDCX). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Its Competitors Rein Therapeutics OnKure Therapeutics Biodexa Pharmaceuticals Iterum Therapeutics Alterity Therapeutics Akari Therapeutics Acrivon Therapeutics Eliem Therapeutics Barinthus Biotherapeutics Medicus Pharma Rein Therapeutics (NASDAQ:RNTX) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings. Do insiders & institutionals believe in RNTX or GEMP? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by company insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, RNTX or GEMP? Rein Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Is RNTX or GEMP more profitable? Rein Therapeutics' return on equity of -74.08% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -74.08% -27.93% Gemphire Therapeutics N/A -419.70%-173.05% Does the MarketBeat Community favor RNTX or GEMP? Gemphire Therapeutics received 289 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRein TherapeuticsN/AN/AGemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% Which has preferable earnings and valuation, RNTX or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$15.73M-$2.86-0.66Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Does the media refer more to RNTX or GEMP? In the previous week, Rein Therapeutics had 3 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 0 mentions for Gemphire Therapeutics. Rein Therapeutics' average media sentiment score of 0.30 beat Gemphire Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Rein Therapeutics Neutral Gemphire Therapeutics Neutral SummaryRein Therapeutics beats Gemphire Therapeutics on 6 of the 9 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.89M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.4626.7519.65Price / SalesN/A261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book1.366.526.964.59Net Income-$23.64M$143.26M$3.23B$248.23M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.73-2.4%N/A-80.8%$10.89MN/A0.009High Trading VolumeRNTXRein TherapeuticsN/A$1.91-3.5%N/AN/A$42.31MN/A-0.619News CoverageOKUROnKure Therapeutics3.1815 of 5 stars$3.12+8.5%$32.33+938.0%N/A$42.08MN/A-0.26N/ANews CoverageGap UpBDRXBiodexa Pharmaceuticals0.5016 of 5 stars$1.15flatN/AN/A$42.03M$83K0.0020Short Interest ↑ITRMIterum Therapeutics2.4015 of 5 stars$1.03+0.5%$9.00+778.0%-13.8%$41MN/A-0.7810News CoverageAnalyst RevisionGap DownATHEAlterity Therapeutics2.1126 of 5 stars$4.57-5.7%$12.00+162.9%+136.6%$40.48MN/A0.0010Gap DownAKTXAkari TherapeuticsN/A$1.25-0.4%N/A-62.3%$40.06MN/A0.009Positive NewsACRVAcrivon Therapeutics4.1254 of 5 stars$1.28-0.4%$17.71+1,289.4%-83.4%$39.98MN/A-0.4758News CoverageAnalyst RevisionELYMEliem TherapeuticsN/A$1.34-3.6%N/A-85.7%$39.87MN/A-2.539Gap DownBRNSBarinthus Biotherapeutics2.8362 of 5 stars$0.99-0.2%$5.17+422.9%-50.6%$39.86M$14.97M-0.66107Gap UpMDCXMedicus Pharma1.7637 of 5 stars$2.88flat$23.50+716.0%N/A$39.09MN/A0.00N/ANews CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies Rein Therapeutics Competitors OnKure Therapeutics Competitors Biodexa Pharmaceuticals Competitors Iterum Therapeutics Competitors Alterity Therapeutics Competitors Akari Therapeutics Competitors Acrivon Therapeutics Competitors Eliem Therapeutics Competitors Barinthus Biotherapeutics Competitors Medicus Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GEMP Stock Free GEMP Stock Alerts